

Shigella dysenteriae serotype 1 in West Africa: Intervention strategy for an outbreak in Sierra Leone 1999-2000

ICEID, Atlanta, 25th March 2002

PJ. Guerin, C. Brasher, E. Baron, D. Mic, F. Grimont, M. Ryan, P. Aavitsland and D. Legros

Bacillary dysentery

- Major cause of morbidity and mortality in developing countries:
 - Shigella dysenteriae type 1 (Sd1)
- 1980 and 1990s:
 - Large outbreaks in Central and Southern Africa
 - Increased antibiotic resistance
- Without treatment: mortality of 5 to 15 %

Objectives

- To describe the outbreak
- To evaluate the outcome of ciprofloxacin treatment

Methods: Outbreak investigation

- Case definition:
 - Southern part of Kenema district
 - Bloody diarrhoea observed by health workers
 - December 1999 March 2000
- Field laboratory in Kenema hospital
- Descriptive analysis
 - Attack rate
 - Case fatality ratio (CFR) in general pop. / isolation centres

Methods: Evaluation of treatment

- Patients at high risk of death from dysentery
 - Age <5 or >50 years
 - Malnourished older children and adults
 - Severe cases: Dehydration, fever > 38.5 °C, convulsion or coma
 - → Isolation centres
 - → 5 day oral treatment: ciprofloxacin
- Other patients
 - →Hygiene advice
 - →Oral rehydration





From Dec 1999 to March 2000

- 4,218 new cases of bloody diarrhoea
- 131 deaths

| | Total | < 5 years | ≥ 5 years | р |
|----------------|-------|-----------|-----------|---------|
| Attack rate | 7.5 % | 11.2 % | 6.8 % | < 0.001 |
| CFR | 3.1 % | 6.1 % | 2.1 % | 0.001 |

Cases of bloody diarrhoea reported per week, Sierra Leone, 1999-2000





Isolation centres

- 583 patients treated
- CFR: 0.9 % (5 deaths)
- Median length of symptoms before hospitalisation: 3 days
- Treatment compliance cipro 5 days: 99.7 %



- First large outbreak caused by Sd1 reported in West Africa
- Active screening of cases in villages:
 - Quick access to treatment
- Low case fatality
 - 5 day ciprofloxacin regimen: highly effective
 - Hygiene advice

Therapeutic choice: ciprofloxacin

- Drawbacks of nalidixic acid
 - Poor compliance to treatment: 4 times a day, side effects
 - Less effective than ciprofloxacin
 - Increased resistance to NA: From 36% to 66% in 4 months
 - First step to resistance to 2nd generation quinolones

Perspectives

- Reconsider recommendations
 - Treatment protocol in outbreak situation
- Cost and availability of antibiotics
 - Access to generics of ciprofloxacin
 - Negotiated prices of ciprofloxacin
- Operational research:
 - Shorter therapeutic protocols
 - Vaccines

Acknowledgements

- Ministry of health, Freetown, Sierra Leone
- Epicentre, Paris, France
- European Programme for Intervention Epidemiology Training (EPIET)
- Norwegian Institute of Public Health, Oslo, Norway
- MÈdecins Sans FrontiËres, Paris, France
- > Institut Pasteur (CNRTME), Paris, France
- Department of Communicable Disease Surveillance and Response, World Health Organisation, Geneva, Switzerland











folkehelseinstituttet





Sd1 resistance pattern to antibiotics Evolution resistance strains rate to cotrimoxazole and nalidixic acid Benaco camp, Tanzania, 1994

| Antibiotic | July | October | November |
|---------------|------|---------|----------|
| n | 42 | 31 | 30 |
| Cotrimo | 57% | 78% | 89% |
| Nalidixic Ac. | 36% | 47% | 66% |



SD1 strains resistance pattern to antibiotics East and Central Africa 1994 ñ Sierra Leone 2000

| | Countries | n | Ampi | Cotrim | Nalid. Ac. | Cipro |
|------|--------------|-----|------|--------|------------|-------|
| 1994 | Tanzania | 30 | 100% | 89% | 66% | 0% |
| | Rwanda | 40 | 100% | 100% | 97% | 0% |
| | | 44 | ND | 97% | 91% | 0% |
| | DRC | 82 | 98% | 100% | 98% | 0% |
| | | | | | | |
| 2000 | Sierra Leone | 126 | 100% | 100% | 0% | 0% |